|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5590867||1404721||2017||3 صفحه PDF||سفارش دهید||دانلود کنید|
- A 54-year-old black woman with MS developed follicular lymphoma after 8 months of therapy with teriflunomide.
- This is the first published case of a patient developing lymphoma while receiving teriflunomide treatment.
- At least 10 more cases have so far been reported to pharmacovigilance worldwide.
- An association between teriflunomide and a higher risk of lymphoma cannot be excluded.
Teriflunomide is an oral therapy approved for relapsing forms of multiple sclerosis which has been shown to reduce relapse rate and disability progression. We report the case of a 54-year -old black woman with multiple sclerosis who developed follicular lymphoma after about 8 months of exposure to teriflunomide. Importantly, apart from age, the patient had none of the established risk factors for follicular lymphoma. Moreover, although this is the first published case of a lymphoma on teriflunomide, it is not the first confirmed case. Ten other cases have so far been reported to pharmacovigilance worldwide, and a further 82 with leflunomide. In conclusion, an association between teriflunomide and a higher risk of lymphoma cannot be ruled out.
Journal: Multiple Sclerosis and Related Disorders - Volume 17, October 2017, Pages 92-94